ABBV vs ABVX: Which Is the Better Buy in 2026?
Last updated November 2026
Short answer
ABBV is the larger of the two ($517.84B market cap): the incumbent the market prices for continued execution (18.10x forward earnings, beta 0.19). ABVX is the smaller challenger ($7.95B), priced similarly on forward earnings (-23.67x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.
ABBV vs ABVX: the tie-breaker metrics
Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | ABBV | ABVX | What it tells you |
|---|---|---|---|
| Market cap | $517.84B | $7.95B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 18.10 | -23.67 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Beta | 0.19 | -0.33 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 91% of range | 27% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
Before you buy: how ABBV and ABVX affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ABBV and ABVX share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ABBV and ABVX exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does AbbVie (ABBV) do?
AbbVie is a North Chicago-based research-driven biopharmaceutical company spun off from Abbott Laboratories in 2013. It focuses on discovering and commercializing medicines for immunology, oncology, neuroscience, and aesthetics. Its immunology franchise anchors the business: historically through Humira (adalimumab), and increasingly through Skyrizi (risankizumab) and Rinvoq (upadacitinib), which treat conditions such as plaque psoriasis, Crohn's disease, rheumatoid arthritis, and ulcerative colitis. Oncology contributes through Imbruvica (developed in collaboration with Johnson and Johnson) and Venclexta (in collaboration with Roche), while the 2020 acquisition of Allergan added Botox Therapeutic, Vraylar, and the aesthetics portfolio including Botox Cosmetic and Juvederm. Revenue is generated by selling branded pharmaceuticals at negotiated prices to wholesale distributors, specialty pharmacies, and health systems across more than 175 countries.
What does Abivax SA (ABVX) do?
Abivax SA is a French clinical-stage biopharmaceutical company listed on Nasdaq via a sponsored ADR (ABVX). Its lead and effectively sole value driver is obefazimod (formerly ABX464), a first-in-class oral miR-124 enhancer being developed for inflammatory bowel disease. In 2025 and 2026 the registrational Phase 3 ABTECT program in moderate-to-severe ulcerative colitis reported positive results across both induction trials and the maintenance trial, with the 50 mg dose showing clinical remission around 51% at Week 44 versus roughly 10% for placebo; maintenance results came on June 1, 2026 and Part 2 results with the maintenance safety database on June 29. A pre-NDA interaction with the FDA followed on July 30, management plans to file the U.S. new drug application at the end of 2026, and a Phase 2b Crohn's disease readout (ENHANCE-CD) is expected around mid-2027.
ABBV vs ABVX: how do they differ?
Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.
- ABBV drivers: Skyrizi and Rinvoq replacing Humira faster than expected; Neuroscience becoming a meaningful second growth engine.
- ABVX drivers: Positive Phase 3 obefazimod data; Path to an FDA filing.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: The single largest structural risk is portfolio concentration: Skyrizi and Rinvoq together account for a rapidly growing share of total revenue, meaning any clinical setback, competitive entry in atopic dermatitis (where Regeneron's Dupixent holds a strong position), or government-mandated price cut under the Inflation Reduction Act could materially impair the growth outlook. For ABVX, as a single-asset biotech, essentially all of Abivax's value depends on obefazimod, so a regulatory rejection, a delay, or a negative safety finding could sharply reduce the shares.
ABBV or ABVX: which should you pick?
Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick ABBV if you believe its drivers more; ABVX if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ABBV and ABVX guides.
ABBV vs ABVX: the full fundamentals
ABBV. The large gap between the trailing GAAP P/E (about 80x, inflated by non-cash acquired IPR and D charges on recent deals) and the forward P/E of roughly 17.5x illustrates why analysts and management prefer adjusted metrics: upfront licensing and milestone payments depress reported earnings without reducing cash generation. The forward multiple has risen from about 15.7x in June as the shares climbed, so more of the expected Skyrizi and Rinvoq growth is now in the price. Q3 2026 results on October 30 are the next test, with consensus EPS near $3.79.
ABVX. Abivax has effectively no product revenue and posts large net losses, which is normal for a clinical-stage biotech funding late-stage trials and launch preparation rather than a warning sign on its own. Traditional earnings multiples do not apply; the market instead values the probability-weighted potential of obefazimod reaching and selling in the market, and after the 2026 pullback the roughly $7.75B market cap sits well below the average analyst target of about $164 per ADR. The mid-2026 capital raise materially extended the runway and reduced near-term financing risk.
Headline figures (approximate, October 2026): ABBV shows revenue (ttm) ~$64.4 billion (Q2 2026 ~$17.0B, up ~10% YoY), adjusted eps Q2 2026 $3.65 vs $3.61 estimate; FY2026 guidance $13.87-14.07; FY2027 consensus ~$16.21, gaap net income (ttm) ~$6.3 billion (GAAP EPS ~$3.54, depressed by acquired IPR and D), p/e ~80x trailing GAAP; ~17.5x forward adjusted; ABVX shows market cap ~$7.75B, share price (oct 16, 2026) ~$89 (52-week range ~$70-149), revenue (ttm) ~negligible (~$4.7M, pre-commercial), net loss (h1 2026) ~EUR 166M.
The bottom line: ABBV vs ABVX
ABBV and ABVX are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined ABBV and ABVX exposure against your real portfolio. It is not an investment adviser.
Wondering how ABBV or ABVX fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about AbbVie
Ask Walnut's AI anything about ABBV and see how it fits what you own.
FAQ
What is the difference between ABBV and ABVX?
+
AbbVie is a North Chicago-based research-driven biopharmaceutical company spun off from Abbott Laboratories in 2013. Abivax SA is a French clinical-stage biopharmaceutical company listed on Nasdaq via a sponsored ADR (ABVX). They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is ABBV or ABVX the better stock?
+
Neither is universally better. ABBV is the larger incumbent; ABVX is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, ABBV or ABVX?
+
On forward P/E (as of November 2026), ABBV trades at 18.10x and ABVX at -23.67x, so ABVX is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both ABBV and ABVX?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of ABBV vs ABVX?
+
ABBV: The single largest structural risk is portfolio concentration: Skyrizi and Rinvoq together account for a rapidly growing share of total revenue, meaning any clinical setback, competitive entry in atopic dermatitis (where Regeneron's Dupixent holds a strong position), or government-mandated price cut under the Inflation Reduction Act could materially impair the growth outlook. AbbVie also carries a heavy debt load, about $70.9 billion as of mid-2026, a legacy of the Allergan acquisition, constraining financial flexibility if credit markets tighten or a major pipeline bet fails. GAAP earnings are depressed by acquired research charges, so the dividend exceeds trailing GAAP net income (a payout ratio near 190%), and it is covered by cash flow rather than reported profit. Integrating acquisitions such as Apogee Therapeutics introduces execution risk, the aesthetics segment (Botox Cosmetic, Juvederm) has shown sensitivity to consumer spending cycles, and after a 24% gain in 2026 the shares trade slightly above the mean analyst target of about $283. ABVX: As a single-asset biotech, essentially all of Abivax's value depends on obefazimod, so a regulatory rejection, a delay, or a negative safety finding could sharply reduce the shares. Malignancy signals at the 50 mg dose have been a focal regulatory question, even though integrated safety data reported rates in line with background disease incidence. The ulcerative colitis market is crowded with established therapies such as Rinvoq, Skyrizi, Zeposia, and Entyvio, so commercial success is not guaranteed even after approval. The company generates negligible revenue and large net losses (about EUR 401M over the trailing twelve months, with spending rising as launch preparation begins), and repeated equity raises have diluted shareholders. The roughly 34% fall in the ADR over three months to October 2026 shows how volatile sentiment remains even after positive data. Approval, launch execution, a leadership transition in the medical function, and any partnership or acquisition outcome all remain uncertain.
Related comparisons
Browse all stock comparisons.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell ABBV or ABVX; figures are approximate and dated (as of November 2026). Verify current data before investing.